Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
87,497,812
-
Share change
-
+288,463
-
Total reported value
-
$3,681,153,433
-
Put/Call ratio
-
127%
-
Price per share
-
$42.07
-
Number of holders
-
309
-
Value change
-
+$1,949,206
-
Number of buys
-
146
-
Number of sells
-
149
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2024
As of 31 Dec 2024,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
309 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,497,812 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., SANDS CAPITAL MANAGEMENT, LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, Clearbridge Investments, LLC, FEDERATED HERMES, INC., RTW INVESTMENTS, LP, and Rock Springs Capital Management LP.
This page lists
309
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.